Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial.

Yao H, Zhang Q, Li H, Yin Y, Wang S, Ouyang Q, Sun T, Li W, Wang X, Yan M, Wang B, Cheng J, Tong Z, Wei W, Wang X, Xie W, Sun Z, Yuan P, Geng C, Gan L, Han X, Li W, Zhou S, Yan X, Gao J, Yi T, Wu J, Niu Z, Fu F, Nie J, Wang Y, Zhao B, Wu Z, Zhu Z, Yang Y, Zhao J, Sheng Z, Zhang Y, Cheng L, Zhu X, Song E

Open source

DOI: 10.1016/s1470-2045(26)00193-2
Published: 2026 Aug
Container: The Lancet. Oncology
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-26-00193-2,
  title = {Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial.},
  author = {Yao H and Zhang Q and Li H and Yin Y and Wang S and Ouyang Q and Sun T and Li W and Wang X and Yan M and Wang B and Cheng J and Tong Z and Wei W and Wang X and Xie W and Sun Z and Yuan P and Geng C and Gan L and Han X and Li W and Zhou S and Yan X and Gao J and Yi T and Wu J and Niu Z and Fu F and Nie J and Wang Y and Zhao B and Wu Z and Zhu Z and Yang Y and Zhao J and Sheng Z and Zhang Y and Cheng L and Zhu X and Song E},
  year = {2026},
  journal = {The Lancet. Oncology},
  doi = {10.1016/s1470-2045(26)00193-2},
  url = {https://doi.org/10.1016/s1470-2045(26)00193-2}
}

RIS

TY  - JOUR
TI  - Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial.
AU  - Yao H
AU  - Zhang Q
AU  - Li H
AU  - Yin Y
AU  - Wang S
AU  - Ouyang Q
AU  - Sun T
AU  - Li W
AU  - Wang X
AU  - Yan M
AU  - Wang B
AU  - Cheng J
AU  - Tong Z
AU  - Wei W
AU  - Wang X
AU  - Xie W
AU  - Sun Z
AU  - Yuan P
AU  - Geng C
AU  - Gan L
AU  - Han X
AU  - Li W
AU  - Zhou S
AU  - Yan X
AU  - Gao J
AU  - Yi T
AU  - Wu J
AU  - Niu Z
AU  - Fu F
AU  - Nie J
AU  - Wang Y
AU  - Zhao B
AU  - Wu Z
AU  - Zhu Z
AU  - Yang Y
AU  - Zhao J
AU  - Sheng Z
AU  - Zhang Y
AU  - Cheng L
AU  - Zhu X
AU  - Song E
PY  - 2026
JO  - The Lancet. Oncology
DO  - 10.1016/s1470-2045(26)00193-2
UR  - https://doi.org/10.1016/s1470-2045(26)00193-2
ER  -

APA

H, Y., Q, Z., H, L., Y, Y., S, W., Q, O., T, S., W, L., X, W., M, Y., B, W., J, C., Z, T., W, W., X, W., W, X., Z, S., P, Y., C, G., L, G., X, H., W, L., S, Z., X, Y., J, G., T, Y., J, W., Z, N., F, F., J, N., Y, W., B, Z., Z, W., Z, Z., Y, Y., J, Z., Z, S., Y, Z., L, C., X, Z., & E, S. (2026). Trastuzumab rezetecan versus pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer (HORIZON-Breast01): interim analysis of a multicentre, open-label, randomised, controlled, phase 3 trial.. The Lancet. Oncology. https://doi.org/10.1016/s1470-2045(26)00193-2

Source records

pubmed · retrieved 2026-09-26T21:53:04.277Z